A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Pheon Therapeutics
Takeda
Tempus AI
Alaunos Therapeutics
Mirati Therapeutics Inc.
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Mirati Therapeutics Inc.
NantCell, Inc.
ADC Therapeutics S.A.
HiberCell, Inc.
pharmaand GmbH
MacroGenics
University Health Network, Toronto
CureOne
National Institutes of Health Clinical Center (CC)
Helsinn Healthcare SA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
New York State Psychiatric Institute
Stanford University
National Cancer Institute (NCI)
Calando Pharmaceuticals
Auron Healthcare GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
Cancer Research UK
Vanderbilt-Ingram Cancer Center